Overview

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects

Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This study will have one stage consisting of multiple treatment visits. The study is designed to assess the safety and bioavailability of Entera's oral PTH(1 - 34) in adult male healthy volunteers in various formulation. The study is also designed to assess the reproducibility of pharmacokinetic profiles with various formulations.
Phase:
Phase 1
Details
Lead Sponsor:
Entera Bio Ltd.
Treatments:
Parathyroid Hormone
Teriparatide